Genfit’s in-development drug for a pervasive liver disease failed to beat placebo in a midstage trial, but the company, undaunted, is setting sights on late-stage studies with eyes on what could be a blockbuster market.

…read more

Source: Genfit’s NASH drug flunks Phase II, but management sees a silver lining


0 No comments